Regeneron (REGN) Tops Q4 EPS by $5.35
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Pharma (REGN) PT Raised to $640 at Cowen
February 4, 2022 12:55 PM ESTCowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $640.00 (from $625.00) while maintaining a Market Perform rating following reuslts.
The analyst commented, "A strong commercial performance of the core business led to strong Q4 results. Understanding... More
